Table 1.
Patients’ characteristics by year of diagnosis.
| Characteristic | 2019 (%) | 2020(%) | P-valuea |
|---|---|---|---|
| Patients | 506 | 360 | |
| Monthly access rate | 51 | 36 | <.01b |
| Median age (IQR) | 71 (range 31-95) | 70 (range 21-94) | .29 |
| Gender | .29 | ||
| Female | 218 (43) | 169 (47) | |
| Male | 288 (57) | 191 (53) | |
| Asymptomatic disease onset*c | 108 (21) | 63 (18) | .11 |
| Sidedness of primitive lesionc | .24 | ||
| Right (until splenic flexure) | 213 (45) | 142 (40) | |
| Left | 265 (55) | 211 (60) | |
| Stage at diagnosisc | <.01b | ||
| Stages I-II-III | 388 (78) | 225 (63) | |
| Stage IV | 112 (22) | 130 (37) | |
| Mutational statusc | .04b | ||
| Wild type | 88 (50) | 58 (39) | |
| Mutant | 87 (50) | 92 (61) | |
| Treatmentc | <.01b | ||
| Adjuvant | 133 (27) | 101 (29) | |
| Neoadjuvant | 71 (14) | 58 (16) | |
| Metastatic | 79 (16) | 102 (29) | |
| Adjuvant post-metastasectomy | 14 (3) | 8 (2) | |
| Follow up | 194 (40) | 83 (24) | |
| MTD discussionc | <.01b | ||
| Yes | 253 (50) | 138 (38) | |
| No | 250 (50) | 221 (62) | |
| Treatment within clinical trialsc | .35 | ||
| Yes | 5 (1) | 6 (2) | |
| No | 417 (99) | 301 (98) | |
| Radiotherapyc | 1.00 | ||
| Yes | 71 (19) | 51 (19) | |
| No | 311 (81) | 224 (81) | |
| ECOG PS at start of treatmentc | .61 | ||
| 0 | 192 (57) | 156 (59) | |
| 1 | 130 (38) | 90 (34) | |
| 2 | 15 (4) | 16 (6) | |
| 3 | 2 (1) | 1 (0) |
Chi-square test comparing proportions between 2019 and 2020. P-values were calculated excluding unknown values.
Statistically significant (P < .05).
% has been calculated excluding NA (not available) values.
Abbreviations: IQR, interquartile range; MDT, multidisciplinary team; ECOG PS, Eastern Cooperative Oncology Group performance status.